

Note: This document has been translated from the Japanese-language original (hereinafter, the “original”) for reference purposes only. In the event of any discrepancy between this translated document and the original, the original shall prevail.



Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 [IFRS]

October 30, 2026

Company Name: SUMITOMO PHARMA CO., LTD.
Stock Exchange Listings: Tokyo
Security Code Number: 4506 (URL <https://www.sumitomo-pharma.com>)
Representative: Toru Kimura, Representative Director, President and Chief Executive Officer
Contact: Megumi Maruyama, Vice President, Head of Corporate Communications
Telephone: 06-6203-5321
Filing Date of Semi-annual Securities Report: November 2, 2026
Starting Date of Dividend Payments: —
Preparation of Supplementary Financial Data for Quarterly Financial Results: Yes
Information Meeting for Financial Results to be held: Yes (for institutional investors, analysts and the press)

(Note: All amounts are rounded to the nearest million JPY)

1. Consolidated Financial Results for the Six Months Ended September 30, 2026 (April 1, 2026 to September 30, 2026)

(1) Results of Operations

(% represents changes from the previous year)

	Revenue		Core operating profit		Operating profit		Net profit		Net profit attributable to owners of the parent		Total comprehensive income	
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%
Six months ended September 30, 2026	266,490	17.3	42,123	(56.2)	42,276	(56.0)	38,238	(61.3)	38,238	(61.3)	41,460	(56.9)
Six months ended September 30, 2025	227,122	25.7	96,084	—	96,157	—	98,860	—	98,860	—	96,109	—

Reference: Profit before taxes Six months ended September 30, 2026: 39,382 million JPY

Six months ended September 30, 2025: 92,802 million JPY

“Core operating profit” is calculated by deducting certain items from operating profit.

	Basic earnings per share	Earnings per share (diluted)
	JPY	JPY
Six months ended September 30, 2026	86.48	—
Six months ended September 30, 2025	248.84	—

(2) Financial Position

	Total assets	Net assets	Equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets	Equity attributable to owners of the parent per share
	Millions of JPY	Millions of JPY	Millions of JPY	%	JPY
As of September 30, 2026	851,053	431,105	431,105	50.7	961.02
As of March 31, 2026	804,571	292,467	292,467	36.4	736.16

2. Dividends

	Dividends per share				
	1st quarter	2nd quarter	3rd quarter	Year-End	Annual
	JPY	JPY	JPY	JPY	JPY
Fiscal year ended March 31, 2026	—	0.00	—	0.00	0.00
Fiscal year ending March 31, 2027	—	0.00			
Fiscal year ending March 31, 2027 (Forecasts)			—	15.00	15.00

Note: Revision of dividend forecasts from the latest announcement: Yes

For details regarding the revision to the annual dividend forecast, please refer to the “Sumitomo Pharma Announces Revision of Its Annual Dividend Forecast for the Fiscal Year Ending March 31, 2027” released today.

3. Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

(% represents changes from the previous year)

	Revenue		Core operating profit		Operating profit		Net profit attributable to owners of the parent		Earnings per share
	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	Millions of JPY	%	JPY
Fiscal year ending March 31, 2027	565,000	24.6	105,000	(0.9)	104,000	(3.1)	94,000	(12.0)	211.07

Note: Revision of consolidated financial forecasts from the latest announcement: Yes

***Notes:**

(1) Significant changes in the scope of consolidation during the period: None

(New: None)

(Excluded: None)

(2) Changes in accounting policies, accounting estimates

① Changes in accounting policy required by IFRS: Yes

② Changes in accounting policy due to other reasons: None

③ Changes in accounting estimates: None

Note: For details, please refer to “2. Condensed Consolidated Financial Statements and Major Notes (5) Notes to Condensed Consolidated Financial Statements (Material Accounting Policies)” on page 11 of Attachment Documents.

(3) Number of shares issued (Common stock)

① Number of shares issued (Including treasury stock) at the end of period

As of September 30, 2026 449,204,554 shares

As of March 31, 2026 397,900,154 shares

② Number of treasury stock at the end of period

As of September 30, 2026 611,469 shares

As of March 31, 2026 611,105 shares

③ Average number of shares outstanding during the period

Six months ended September 30, 2026 442,145,122 shares

Six months ended September 30, 2025 397,289,755 shares

** This summary of consolidated financial results is exempt from audit procedures.*

** Explanation for Appropriate Use of Forecasts and Other Notes:*

- This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of disclosure of such statements and involve both known and unknown risks and uncertainties. Accordingly, due to various subsequent factors, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein. Please refer to page 4 of Attachment Documents, “1. Qualitative Information of Financial Results for the Six Months Ended September 30, 2026 (5) Consolidated Financial Forecasts.”

- Information concerning pharmaceuticals and other products (including those under development) contained herein is not intended as advertising or as medical advice.

- Supplementary financial data and the presentation materials for the earnings presentation are disclosed together with this summary.

- The Company holds an earnings presentation for institutional investors, analysts and the press on Friday, October 30, 2026. The video of the presentation will be posted on its website promptly after the presentation.

【Attachment Documents】

1. Qualitative Information of Financial Results for the Six Months Ended September 30, 2026.....	2
(1) Business Results	2
(2) Financial Condition	3
(3) Cash Flows	3
(4) Research and Development Activities.....	3
(5) Consolidated Financial Forecasts	4
2. Condensed Consolidated Financial Statements and Major Notes	5
(1) Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of Comprehensive Income	5
(2) Condensed Consolidated Statement of Financial Position	6
(3) Condensed Consolidated Statement of Changes in Equity	8
(4) Condensed Consolidated Statement of Cash Flows	10
(5) Notes to Condensed Consolidated Financial Statements	11

1. Qualitative Information of Financial Results for the Six Months Ended September 30, 2026

Forward-looking statements contained herein are based on the Group's judgments in light of information available as of the last day of the six-month period.

(1) Business Results

(About the performance indicator of "Core operating profit")

With the adoption of International Financial Reporting Standards(IFRS), the Group has set "core operating profit," which shows the Group's profitability as its original performance indicator.

"Core operating profit" is calculated by deducting certain items from operating profit. The deduction items mainly include impairment losses, business structure improvement expenses, and changes in fair value of contingent consideration.

Highlights of the Group's consolidated financial results for the six months of the fiscal year ending March 31, 2027 are as follows:

(Billions of JPY)				
	Six months ended September 30, 2025	Six months ended September 30, 2026	Change	Change %
Revenue	227.1	266.5	39.4	17.3
Core operating profit	96.1	42.1	(54.0)	(56.2)
Operating profit	96.2	42.3	(53.9)	(56.0)
Profit before taxes	92.8	39.4	(53.4)	(57.6)
Net profit attributable to owners of the parent	98.9	38.2	(60.6)	(61.3)

■ Revenue increased by 17.3% year-on-year to 266.5 billion JPY.

Revenue increased by 39.4 billion JPY year-on-year to 266.5 billion JPY. The increase resulted primarily from expanded sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (therapeutic agent for overactive bladder) in the U.S., as well as the depreciation of the Japanese yen. These factors more than offset the revenue decline resulting from the partial transfer of the Asian business in the corresponding period of the previous fiscal year.

[U.S.]

Revenue increased by 40.8 billion JPY year-on-year to 197.8 billion JPY. Despite the recording of sales milestone revenue from ORGOVYX® in the corresponding period of the previous fiscal year, revenue increased primarily owing to expanded sales of ORGOVYX® and GEMTESA®, as well as the depreciation of the Japanese yen.

[Japan]

Revenue increased by 1.8 billion JPY year-on-year to 44.6 billion JPY. Although the sales partnership for Equa® and EquMet® (both therapeutic agents for type 2 diabetes) expired, revenue increased primarily owing to the Company's commencement of its own sales of XEPLION® and XEPLION TRI® (both long-acting antipsychotic medications), as well as sales growth of TWYMEEG® (therapeutic agent for type 2 diabetes).

[Others]

Revenue decreased by 3.2 billion JPY year-on-year to 24.1 billion JPY. Although sales to Europe increased, revenue decreased primarily due to the impact of the partial transfer of the Asian business in the corresponding period of the previous fiscal year.

■ Core operating profit decreased by 56.2% year-on-year to 42.1 billion JPY.

Although revenue increased, the increase in gross profit was limited, primarily due to changes in the product mix resulting from the partial transfer of the Asian business. Selling, general and administrative expenses increased primarily due to the increase in sales promotion expenses aimed at expanding revenue in the U.S. Research and development expenses also increased due to accelerated clinical development in oncology and the advancement of clinical programs in psychiatry and neurology. These factors, together with the absence of the gains on sales of shares of subsidiaries recorded in the corresponding period of the previous fiscal year following the partial transfer of the Asian business, resulted in a significant decline in core operating profit.

■ **Operating profit decreased by 56.0% year-on-year to 42.3 billion JPY.**

Operating profit decreased mainly due to the decline in core operating profit.

■ **Profit before taxes decreased by 57.6% year-on-year to 39.4 billion JPY.**

Profit before taxes decreased due to the decline in operating profit.

■ **Net profit attributable to owners of the parent decreased by 61.3% year-on-year to 38.2 billion JPY.**

Net profit attributable to owners of the parent decreased due to the decline in profit before taxes.

Previously, the Group disclosed its consolidated financial statements based on geographical reportable segments. Given the increasingly global nature of its business operations, the Group changed to a single segment, Pharmaceutical Business, beginning with the six months ended September 30, 2026. Accordingly, business results based on the Group's former reportable segments have been omitted. For details, please refer to "2. Condensed Consolidated Financial Statements and Major Notes (5) Notes to Condensed Consolidated Financial Statements (Segment Information)."

(2) Financial Condition

Total assets increased by 46.5 billion JPY from the previous fiscal year-end to 851.1 billion JPY.

Non-current assets decreased by 11.6 billion JPY from the previous fiscal year-end, primarily due to a decline in goodwill from foreign currency translation, as well as the return of retirement benefit trust assets.

Current assets increased by 58.1 billion JPY from the previous fiscal year-end, owing to an increase in cash and cash equivalents resulting mainly from the public offering conducted during the six months ended September 30, 2026, as well as an increase in trade and other receivables driven by strong sales in the U.S.

Liabilities decreased by 92.2 billion JPY from the previous fiscal year-end to 419.9 billion JPY as a result of decreases in borrowings and other current liabilities.

Total equity increased by 138.6 billion JPY from the previous fiscal year-end to 431.1 billion JPY as a result of increases in share capital and capital surplus following the public offering conducted during the six months ended September 30, 2026, and an increase in retained earnings following the recording of net profit.

The ratio of equity attributable to owners of the parent to total assets as of September 30, 2026 was 50.7%.

(3) Cash Flows

Cash flows provided by operating activities amounted to 16.7 billion JPY, representing a year-on-year decrease of JPY 1.4 billion. This was primarily due to a decline in net profit, despite the return of retirement benefit trust assets during the six months ended September 30, 2026.

Cash flows provided by investing activities amounted to 0.5 billion JPY, reflecting a year-on-year decrease in net cash inflow of 27.1 billion JPY. This was primarily due to a decrease in proceeds from the loss of control of subsidiaries in the previous fiscal year.

Cash flows provided by financing activities amounted to 17.6 billion JPY, reflecting a year-on-year increase in net cash inflow of 61.5 billion JPY. This was due to proceeds from the issuance of shares during the six months ended September 30, 2026, despite an increase in repayments of borrowings.

After taking into account the effect of exchange rate changes on cash and cash equivalents, the balance of cash and cash equivalents as of September 30, 2026 was 77.8 billion JPY, which represents an increase of 33.4 billion JPY from the previous fiscal year-end.

(4) Research and Development Activities

Research and development expenses for the six months ended September 30, 2026 amounted to 23.8 billion JPY (increased by 35.6% year-on-year). Please note that, excluding the business structure improvement expenses recorded in the corresponding period of the previous fiscal year, research and development expenses on a core basis would have increased by 35.9% year-on-year.

In the oncology area, a pivotal Phase 2 monotherapy study of enzomenib (product code: DSP-5336) in patients with acute myeloid leukemia with NPM1 mutation was initiated in April 2026. In June 2026, enrollment of the number of patients required for the interim analysis was completed in a pivotal Phase 2 monotherapy study of enzomenib in patients with acute leukemia with KMT2A rearrangement.

(5) Consolidated Financial Forecasts

The Company announced that, in light of recent performance trends, it has revised its consolidated financial forecasts for the fiscal year ending March 31, 2027, which were announced on May 13, 2026.

1.Revisions to Its Financial Forecasts for the Fiscal Year Ending March 31, 2027 (April 1, 2026 to March 31, 2027)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
	Millions of JPY	Millions of JPY	Millions of JPY	Millions of JPY	JPY
Previous forecasts (A)	540,000	91,000	90,000	77,000	172.89
Revised forecasts (B)	565,000	105,000	104,000	94,000	211.07
Variance (B-A)	25,000	14,000	14,000	17,000	—
Variance (%)	4.6	15.4	15.6	22.1	—
[Reference] Previous year (Year ended March 31, 2026)	453,294	105,908	107,338	106,865	268.99

Note: The Group has set core operating profit as an original performance indicator and it is calculated by deducting certain items from operating profit. The deduction items mainly include impairment losses, business structure improvement expenses and changes in fair value of contingent consideration.

2.Reasons for the Revisions

In these revised forecasts, the Company has changed its full-year foreign exchange assumption (average exchange rate for the period) from 155.00 JPY per USD in the previous forecast to 157.00 JPY per USD.

Revenue has been revised upward by 25.0 billion JPY from the previous forecast to 565.0 billion JPY, reflecting the expectation that sales in the U.S., led by GEMTESA®, will exceed the initial forecast, as well as an increase arising from the revised foreign exchange assumption.

Core operating profit has been revised upward by 14.0 billion JPY from the previous forecast to 105.0 billion JPY, reflecting an expected increase in gross profit from higher revenue, while higher selling expenses associated with further commercial expansion are also expected.

Reflecting the increase in core operating profit, operating profit has been revised upward by 14.0 billion JPY from the previous forecast to 104.0 billion JPY, and net profit attributable to owners of the parent has been revised upward by 17.0 billion JPY to 94.0 billion JPY.

Note: Consolidated Financial Forecasts above are based on the certain assumptions considered reasonable and on information available at the time of disclosure of such statements. Accordingly, actual financial results may differ from those presented herein caused by various factors thereafter.

2. Condensed Consolidated Financial Statements and Major Notes

(1) Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of Comprehensive Income

Condensed Consolidated Statement of Profit or Loss

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Revenue	227,122	266,490
Cost of sales	89,701	123,525
Gross profit	137,421	142,965
Selling, general and administrative expenses	76,561	78,716
Research and development expenses	17,524	23,756
Other income	52,772	1,306
Other expenses	496	757
Share of profit of investments accounted for using the equity method	545	1,234
Operating profit	96,157	42,276
Finance income	1,239	1,577
Finance costs	4,594	4,471
Profit before taxes	92,802	39,382
Income tax expenses	(6,058)	1,144
Net profit	98,860	38,238
Net profit attributable to:		
Owners of the parent	98,860	38,238
Net profit	98,860	38,238
Earnings per share (JPY)		
Basic earnings per share	248.84	86.48

Condensed Consolidated Statement of Comprehensive Income

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net profit	98,860	38,238
Other comprehensive income		
Items that will not be reclassified to profit or loss:		
Changes in financial assets measured at fair value through other comprehensive income	724	515
Remeasurements of defined benefit liability/asset		
Share of other comprehensive income of investments accounted for using the equity method	—	4,620
Items that may be reclassified subsequently to profit or loss:		
Changes in financial assets measured at fair value through other comprehensive income	58	—
Exchange differences on translation of foreign operations	(3,533)	(2,006)
Share of other comprehensive income of investments accounted for using the equity method	—	120
Total other comprehensive income	(2,751)	3,222
Total comprehensive income	96,109	41,460
Total comprehensive income attributable to:		
Owners of the parent	96,109	41,460
Total comprehensive income	96,109	41,460

(2) Condensed Consolidated Statement of Financial Position

(Millions of JPY)

	As of March 31, 2026	As of September 30, 2026
Assets		
Non-current assets		
Property, plant and equipment	44,231	44,295
Goodwill	211,098	207,678
Intangible assets	160,474	154,039
Other financial assets	44,703	58,568
Income taxes receivable	7,234	7,117
Retirement benefit assets	19,463	—
Investments accounted for using the equity method	36,400	39,397
Other non-current assets	1,295	1,837
Deferred tax assets	421	756
Total non-current assets	525,319	513,687
Current assets		
Inventories	85,414	90,485
Trade and other receivables	131,414	152,046
Other financial assets	5,327	6,851
Income taxes receivable	3,273	245
Other current assets	9,514	9,980
Cash and cash equivalents	44,310	77,759
Total current assets	279,252	337,366
Total assets	804,571	851,053

	(Millions of JPY)	
	As of March 31, 2026	As of September 30, 2026
Liabilities and equity		
Liabilities		
Non-current liabilities		
Bonds and borrowings	179,056	119,692
Other financial liabilities	16,563	16,563
Retirement benefit liabilities	5,663	5,643
Other non-current liabilities	23,486	15,204
Deferred tax liabilities	15,836	14,922
Total non-current liabilities	240,604	172,024
Current liabilities		
Borrowings	38,130	20,000
Trade and other payables	56,698	61,778
Other financial liabilities	35,217	40,105
Income taxes payable	1,120	5,090
Provisions	89,566	88,369
Other current liabilities	50,769	32,582
Total current liabilities	271,500	247,924
Total liabilities	512,104	419,948
Equity		
Share capital	22,400	71,321
Capital surplus	—	48,258
Treasury shares	(684)	(685)
Retained earnings	158,981	200,284
Other components of equity	111,770	111,927
Equity attributable to owners of the parent	292,467	431,105
Total equity	292,467	431,105
Total liabilities and equity	804,571	851,053

(3) Condensed Consolidated Statement of Changes in Equity

(Millions of JPY)

	Equity attributable to owners of the parent					
	Share capital	Capital surplus	Treasury shares	Retained earnings	Other components of equity	
					Changes in financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit liability/asset
Balance as of April 1, 2025	22,400	—	(682)	46,784	9,306	—
Net profit	—	—	—	98,860	—	—
Other comprehensive income	—	—	—	—	782	—
Total comprehensive income	—	—	—	98,860	782	—
Issuance of new shares	—	—	—	—	—	—
Purchase of treasury shares	—	—	(0)	—	—	—
Reclassification from other components of equity to retained earnings	—	—	—	1,872	(1,872)	—
Total transactions with owners	—	—	(0)	1,872	(1,872)	—
Balance as of September 30, 2025	22,400	—	(682)	147,516	8,216	—

Balance as of April 1, 2026	22,400	—	(684)	158,981	8,768	—
Net profit	—	—	—	38,238	—	—
Other comprehensive income	—	—	—	—	488	4,620
Total comprehensive income	—	—	—	38,238	488	4,620
Issuance of new shares	48,921	48,258	—	—	—	—
Purchase of treasury shares	—	—	(1)	—	—	—
Reclassification from other components of equity to retained earnings	—	—	—	3,065	1,555	(4,620)
Total transactions with owners	48,921	48,258	(1)	3,065	1,555	(4,620)
Balance as of September 30, 2026	71,321	48,258	(685)	200,284	10,811	—

(Millions of JPY)

(millions of JPY)

	Equity attributable to owners of the parent				Total equity
	Other components of equity		Other comprehensive income associated with assets held for sale	Total	
	Exchange differences on translation of foreign operations	Total			
Balance as of April 1, 2025	88,219	97,525	3,452	169,479	169,479
Net profit	—	—	—	98,860	98,860
Other comprehensive income	(81)	701	(3,452)	(2,751)	(2,751)
Total comprehensive income	(81)	701	(3,452)	96,109	96,109
Issuance of new shares	—	—	—	—	—
Purchase of treasury shares	—	—	—	(0)	(0)
Reclassification from other components of equity to retained earnings	—	(1,872)	—	—	—
Total transactions with owners	—	(1,872)	—	(0)	(0)
Balance as of September 30, 2025	88,138	96,354	—	265,588	265,588

Balance as of April 1, 2026	103,002	111,770	—	292,467	292,467
Net profit	—	—	—	38,238	38,238
Other comprehensive income	(1,886)	3,222	—	3,222	3,222
Total comprehensive income	(1,886)	3,222	—	41,460	41,460
Issuance of new shares	—	—	—	97,179	97,179
Purchase of treasury shares	—	—	—	(1)	(1)
Reclassification from other components of equity to retained earnings	—	(3,065)	—	—	—
Total transactions with owners	—	(3,065)	—	97,178	97,178
Balance as of September 30, 2026	101,116	111,927	—	431,105	431,105

(4) Condensed Consolidated Statement of Cash Flows

(Millions of JPY)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Net profit	98,860	38,238
Depreciation and amortization	10,481	9,777
Gain on sales of shares of subsidiaries	(49,043)	—
Impairment losses	1,963	16
Changes in fair value of financial assets and liabilities related to contingent consideration arrangements	(1,500)	(600)
Interest and dividend income	(575)	(890)
Interest expenses	3,844	2,430
Income tax expenses	(6,058)	1,144
(Increase) decrease in trade and other receivables	(44,173)	(23,061)
(Increase) decrease in inventories	9,783	(5,311)
Increase (decrease) in trade and other payables	10,781	5,737
Increase (decrease) in unearned revenue	(6,374)	(6,963)
Increase (decrease) in other financial liabilities	1,466	9,294
Increase or decrease in retirement benefit assets and liabilities	(458)	26,185
Increase in equity instruments resulting from the return of retirement benefit trust assets	—	(15,184)
Increase (decrease) in provisions	6,245	256
Others, net	(14,250)	(26,431)
Subtotal	20,992	14,637
Interest received	435	654
Dividends received	215	238
Interest paid	(2,536)	(1,386)
Income taxes paid	(1,081)	(422)
Income taxes refunded	—	2,952
Net cash provided by (used in) operating activities	18,025	16,673
Cash flows from investing activities		
Purchase of property, plant and equipment	(2,523)	(740)
Proceeds from sales of property, plant and equipment	380	40
Purchase of intangible assets	(1,487)	(661)
Purchase of shares of subsidiaries and associates	(2,338)	(1,670)
Purchase of investments	(786)	(730)
Proceeds from sales and redemption of investments	3,434	3,695
Proceeds from settlement of contingent consideration	—	512
Proceeds from loss of control of subsidiaries	30,477	—
Others, net	477	89
Net cash provided by (used in) investing activities	27,634	535
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(42,530)	(18,130)
Repayments of long-term borrowings	—	(60,000)
Repayments of lease liabilities	(1,304)	(951)
Proceeds from issuance of shares	—	96,875
Dividends paid	(1)	(1)
Others, net	(134)	(213)
Net cash provided by (used in) financing activities	(43,969)	17,580
Net increase (decrease) in cash and cash equivalents	1,690	34,788
Cash and cash equivalents at beginning of year (Condensed Consolidated Statement of Financial Position)	23,116	44,310
Reversal of cash and cash equivalents included in assets held for sale	13,172	—
Cash and cash equivalents at beginning of year	36,288	44,310
Effect of exchange rate changes on cash and cash equivalents	512	(1,339)
Cash and cash equivalents at end of period	38,490	77,759

(5) Notes to Condensed Consolidated Financial Statements

(Notes regarding Going Concern Assumption)

Not applicable.

(Material Accounting Policies)

The material accounting policies applied to the Condensed Consolidated Financial Statements are the same as those for the previous fiscal year's consolidated financial statements, except for the accounting standard provided below.

Income tax expenses for the six months ended September 30, 2026 are calculated based on the estimated average annual effective tax rate.

New or amended Standards and Interpretations		Overview of introduction or amendment
IFRS 7	Financial Instruments: Disclosures	Clarifications to the classification and measurement of financial instruments and disclosure requirements relating to investments in equity instruments
IFRS 9	Financial Instruments	

Beginning with the six months ended September 30, 2026, the Group has adopted the “Amendments to the Classification and Measurement of Financial Instruments (Amendments to IFRS 7 and IFRS 9)”. The adoption of the amendments to IFRS 7 and IFRS 9 does not have a material impact on the Group's Condensed Consolidated Financial Statements.

(Segment Information)

The Group has historically managed its business under three reportable segments (Japan, North America, and Asia), but beginning with the six months ended September 30, 2026, it manages its business as a single operating segment.

In the previous fiscal year, the Group transferred assets, including patent rights for the three key products in the U.S., from its wholly-owned subsidiaries, Sumitomo Pharma Switzerland GmbH and Urovant Sciences GmbH, to the Company, thereby establishing a structure under which the Company is directly involved in the business operations of these products. As a result, the Representative Director, President now makes decisions on the allocation of management resources and evaluates performance for the pharmaceutical business as a whole.

Accordingly, the reportable segments have been consolidated into a single segment, Pharmaceutical Business, and disclosures of revenue and performance by the Group's former reportable segments have been omitted.

(Material Subsequent Event)

Not applicable.